|
Published by: Urch Publishing
Published: Aug. 1, 2007 - 112 Pages
Table of Contents
- Summary
- Introduction
- Key disease markets
- Key drug classes
- Key products
- Key companies
- Key trends and opportunities
- Chapter 1. Introduction
- Global cardiovascular market
- Report overview
- Methodology
- Sources
- Structure
- Chapter 2. Key disease markets
- Key cardiovascular markets
- Disease burden
- Cardiovascular prevalence
- Cardiovascular mortality
- Cardiovascular epidemiology
- Hypertension
- Dyslipidemia
- Coronary heart disease
- Chapter 3. Key drug classes
- Key drug classifications
- Anti-hypertensive drug class
- Leading anti-hypertensive drugs
- Anti-dyslipidemics drug class
- Leading anti-dyslipidemic drugs
- Anti-thrombotics drug class
- Leading anti-thrombotic drugs
- Selected others drug class
- Leading cardiovascular selected others drugs
- Chapter 4. Key products
- Leading products Top 10 leading cardiovascular drugs
- Lipitor (atorvastatin)
- Plavix (clopidogel)
- Norvasc/ Amlodin (amlodopine)
- Zocor (simvastatin)
- Diovan/ Co-Diovan (valsartan)
- Pravachol/ Mevalotin (pravastatin)
- Cozaar/ Hyzaar (losartan)
- Lovenox (enoxaparin)
- Blopress/ Atacand (candesartan)
- Aprovel/ Avapro/ Avalide (irbesartan)
- Chapter 5. Key companies
- Major cardiovascular players Leading companies
- Pfizer
- Merck
- Sanofi-Aventis
- Bristol-Myers Squibb
- Novartis
- AstraZeneca
- Daiichi Sankyo
- Servier
- GlaxoSmithKline
- Boehringer Ingelheim
- Chapter 6. Key trends and opportunities
- Key disease market forecasts
- Global markets
- Cardiovascular sites
- Key drug class forecasts
- Anti-hypertensives
- Anti-dyslipidemics
- Anti-thrombotics
- Selected others
- Key product forecasts
- Lipitor (atorvastatin)
- Plavix (clopidogel)
- Norvasc/ Amlodin (amlodopine)
- Zocor (simvastatin)
- Diovan/ Co-Diovan (valsartan)
- Pravachol/ Mevalotin (pravastatin)
- Cozaar/ Hyzaar (losartan)
- Lovenox (enoxaparin)
- Blopress/ Atacand (candesartan)
- Aprovel/ Avapro/ Avalide (irbesartan)
- Forecast patent expiries
- Key company forecasts
- Pfizer
- Merck
- Sanofi-Aventis
- Bristol-Myers Squibb
- Novartis
- AstraZeneca
- Daiichi Sankyo
- Servier
- GlaxoSmithKline
- Boehringer Ingelheim
- Appendix
- Proprietary data sources
- Product Trends Database
- R&D Trends Database
- Company Trends Database
- Market Trends Database
- Top 58 cardiovascular products
- Top 14 pharmaceutical companies by cardiovascular sales
- List of Figures
- Figure 1: Global cardiovascular market, 2003-2005
- Figure 2: Report structure
- Figure 3: Disease burden for cardio in seven major pharmaceutical markets, 2005
- Figure 4: Prevalence for cardio in seven major pharmaceutical markets, 2005
- Figure 5: Cardio deaths in seven major pharmaceutical markets, 2005
- Figure 6: Hypertension epidemiology in seven major markets, 2005
- Figure 7: Dyslipidemia epidemiology in seven major markets, 2005
- Figure 8: Coronary heart disease epidemiology in seven major markets, 2005
- Figure 9: Global cardiovascular market by drug class, 2005
- Figure 10: Global cardiovascular market by drug class, 2003-2005
- Figure 11: Global cardiovascular market trends by drug class, 2004-2005
- Figure 12: Anti-hypertensives market, 2003-2005
- Figure 13: Leading anti-hypertensive drugs by approval date, 1974-2005
- Figure 14: Anti-dyslipidemics market, 2003-2005
- Figure 15: Leading anti-dyslipidemic drugs by approval date, 1991-2005
- Figure 16: Anti-thrombotic market, 2003-2005
- Figure 17: Leading anti-thrombotic drugs by approval date, 1954-2005
- Figure 18: Cardiovascular selected others market, 2003-2005
- Figure 19: Leading cardiovascular selected others drugs by approval date, 1971-2005
- Figure 20: Top 10 cardiovascular products by global sales, 2005
- Figure 21: Top 10 companies by global cardiovascular sales, 2005
- Figure 22: Top 10 companies by global cardiovascular market share, 2005
- Figure 23: Top 10 companies by global cardiovascular sales, 2004-2005
- Figure 24: Cardiovascular prevalence forecasts by geographic market, 2005-2010
- Figure 25: Cardiovascular prevalence forecasts by disease market, 2005-2010
- Figure 26: Global cardiovascular market forecast, 2003-2010
- Figure 27: Global cardiovascular market forecasts by drug class, 2003-2010
- Figure 28: Top 10 cardiovascular drugs by forecast sales, 2010
- Figure 29: Lipitor (atorvastatin) forecast sales, 2003-2010
- Figure 30: Plavix (clopidogel) forecast sales, 2003-2010
- Figure 31: Norvasc/ Amlodin (amlodopine) forecast sales, 2003-2010
- Figure 32: Zocor (simvastatin) forecast sales, 2003-2010
- Figure 33: Diovan/Co-Diovan (valsartan) forecast sales, 2003-2010
- Figure 34: Pravachol/ Mevalotin (pravastatin) forecast sales, 2003-2010
- Figure 35: Cozaar/ Hyzaar (losartan) forecast sales, 2003-2010
- Figure 36: Lovenox (enoxaparin) forecast sales, 2003-2010
- Figure 37: Blopress/ Atacand (candesartan) forecast sales, 2003-2010
- Figure 38: Aprovel/ Avapro/ Avalide (irbesartan) forecast sales, 2003-2010
- Figure 39: Forecast patent expiries by 2005 global sales, 2006-2015
- Figure 40: Top ten companies by cardiovascular sales trends, 2005-2010
- List of Tables
- Table 1: Global cardiovascular market trends by drug class, 2003-2005
- Table 2: Leading anti-hypertensives drugs, 2005
- Table 3: Anti-hypertensives market trends, 2003-2005
- Table 4: Leading anti-dyslipidemic drugs, 2005
- Table 5: Anti-dyslipidemics market trends, 2003-2005
- Table 6: Leading anti-thrombotic drugs, 2005
- Table 7: Anti-thrombotic market trends, 2003-2005
- Table 8: Leading cardiovascular selected others drugs, 2005
- Table 9: Cardiovascular selected others market trends, 2003-2005
- Table 10: Top 20 cardiovascular products by global sales, 2003-2005
- Table 11: Lipitor (atorvastatin) profile, 2005
- Table 12: Plavix (clopidogel) profile, 2005
- Table 13: Norvasc/ Amlodin (amlodopine) profile, 2005
- Table 14: Zocor (simvastatin) profile, 2005
- Table 15: Diovan/ Co-Diovan (valsartan) profile, 2005
- Table 16: Pravachol/ Mevalotin (pravastatin) profile, 2005
- Table 17: Cozaar/ Hyzaar (losartan) profile, 2005
- Table 18: Lovenox (enoxaparin) profile, 2005
- Table 19: Blopress/ Atacand (candesartan) profile, 2005
- Table 20: Aprovel/ Avapro/ Avalide (irbesartan) profile, 2005
- Table 21: Top 10 companies by global cardiovascular sales, 2003-2005
- Table 22: Pfizer profile, 2005
- Table 23: Pfizer cardiovascular pipeline, 2005
- Table 24: Merck profile, 2005
- Table 25: Merck cardiovascular pipeline, 2005
- Table 26: Sanofi-Aventis profile, 2005
- Table 27: Sanofi-Aventis cardiovascular pipeline, 2005
- Table 28: Bristol-Myers Squibb profile, 2005
- Table 29: Bristol-Myers Squibb cardiovascular pipeline, 2005
- Table 30: Novartis profile, 2005
- Table 31: Novartis cardiovascular pipeline, 2005
- Table 32: AstraZeneca profile, 2005
- Table 33: AstraZeneca cardiovascular pipeline, 2005
- Table 34: Daiichi Sankyo profile, 2005
- Table 35: Daiichi Sankyo cardiovascular pipeline, 2005
- Table 36: Servier profile, 2005
- Table 37: Servier cardiovascular pipeline, 2005
- Table 38: GlaxoSmithKline profile, 2005
- Table 39: GlaxoSmithKline cardiovascular pipeline, 2005
- Table 40: Boehringer Ingelheim profile, 2005
- Table 41: Boehringer Ingelheim cardiovascular pipeline, 2005
- Table 42: Global cardiovascular market forecasts by drug class, 2003-2010
- Table 43: Top 10 cardiovascular drugs forecasts, 2003-2010
- Table 44: Top 10 companies by cardiovascular sales forecasts, 2005-2010
- Table 45: Top 58 cardiovascular products by global pharmaceutical sales, 2003-2005
- Table 46: Top 14 companies by global cardiovascular sales, 2003-2005
AbstractThe global cardiovascular market grew to US$89.7 billion in 2005, a year-on-year increase of 9.6%.
The global cardiovascular market is forecast to expand to US$116.3 billion in 2010, equivalent to a CAGR of 5.3% over the next five years. The slow-down in cardiovascular market growth between 2003 and 2005 is forecast to continue through to 2010. While continued changes in demographics and lifestyle will continue to drive cardiovascular sales forward, growth rates will be limited by continued patent expiries for major products and a dearth of novel therapies being introduced.
Cardiovascular Pharmaceutical Market Trends, 2007 to 2010 - Key market forecasts and growth opportunities provides an in-depth analysis of the growing market for pharmaceutical treatments for cardiovascular disorders including:
- Coronary heart disease
- Cerebrovascular disease
- Peripheral arterial disease
- Rheumatic heart disease
- Congenital heart disease
- Deep vein thrombosis and pulmonary embolism
This comprehensive report, from URCH Publishing, delivers market forecasts and overviews to help inform you in your pharmaceutical business decision-making.
Key findings from the report include:
The global market for cardiovascular patients will increase to 251 million in 2010, with the greatest rate of growth forecast for the US market.
The anti-hypertensives drug class dominates the global cardiovascular market with a market share of nearly 50%.
Of the top 20 products by global cardiovascular sales in 2005, all 20 generated annual sales in excess of US$1 billion.
The top 20 products in 2005 contributed sales of US$59.3 billion accounting for 66.1% of the total cardiovascular market.
A total of 14 pharmaceutical companies were identified as having generated cardiovascular sales in excess of US$1 billion in 2005.
The leading cardiovascular drug projected to achieve the greatest growth over the next five years is Takeda/ AstraZeneca's Blopress/ Atacand (candesartan) with a CAGR of 9.0%
This report provides key information needed in your business including:
Sales forecast for top ten companies providing cardiovascular treatment medicines.
Analysis of leading cardiovascular products likely to loose patent protection in the next ten years.
Sales forecasts to 2010 for the top ten cardio medicines and forecasts by drug class.
Overview of disease incidence, areas of growth and breakdown of disease burden and mortality.
Breakdown of the major market trends and business opportunities
In-depth coverage of the following companies' cardio market presence: AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, GlaxoSmithKline, Merck, Novartis, Pfizer, Sanofi-Aventis, Servier.
Use This Report To: 1. Benchmark your company's portfolio against market trends and forecasts to plan better for greater profitability.
2. Indentify areas of potential pharmaceutical market growth and good opportunities for delivering successful sales growth
3. Support your internal business planning processes by using an external perspective founded on detailed analysis and solid market forecasts.
The 112 page publication contains 40 Figures and 46 Tables to help you make sense of the wealth of data. This report will be of particular use to those involved in:
- pharmaceutical company corporate planning,
- sales and marketing strategy,
- portfolio management, and,
- market and sales forecasting.
The report is divided into five key sections. Chapters 2-5 present historical trends for key disease markets, key drug classes, key products and key companies. Chapter 6 outlines future cardiovascular market trends and major growth opportunities. The data and analysis contained within the report are comprehensive, consistent and up-to-date and thus provide a single-point of reference for understanding cardiovascular market trends
Get Full Details About This Report >>
|
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
|
